Retina

Dr Uwe Oberheide discusses the key findings of his virtual ARVO 2021 presentation on modelling of IOLs for patients with AMD by ray tracing.

Investigators found that a fluocinolone acetonide implant maintained good real-world vision levels in patients with diabetic macular oedema who had good baseline vision.

In a real-world study of patients with treatment-naïve and previously treated diabetic macular oedema, injection of intravitreal dexamethasone 0.7-mg implant provided effective disease control with initial and repeat injections, regardless of reinjection interval.

Topical eye drop treatments for the posterior segment would offer easier, less invasive options than those currently available. This would reduce the burden on both patients and their caregivers, increasing adherence and improving outcomes.

En-face OCT has advantages that make it very useful for characterising macular anatomy and pathologic features of various macular disorders.

Anat Loewenstein, MD, MHA, explores dual Ang-2/VEGF-A inhibition in the management of diabetic macular edema and exudative age-related macular degeneration.

Angiogenesis, Exudation, and Degeneration 2021 Virtual Symposium highlights and thoughts on current treatments options for DME and exudative AMD are discussed. 

In the DRCR Retina Network Protocol V, which studied management strategies for eyes with centre-involving DMO and good visual acuity, the majority of eyes randomly assigned to initial observation completed the 2-year study without needing anti-VEGF therapy for vision loss and nearly one-third had spontaneous resolution of DMO.

Although the majority of patients experience benefit with brolucizumab for the treatment of nAMD without severe adverse events, the risk of retinal vasculitis and/or retinal vascular occlusion needs to be balanced with potential benefits.

Nurses and other allied healthcare professionals can safely and effectively deliver intravitreal steroid implants in a clean room setting, which has reduced patient waiting times.

Aleksandra Rachitskaya, MD, speaks on the current gaps in AMD treatment as well as ongoing retinal advancements to help address unmeet needs of patients.

Recent improvements in electroretinography are making the technique more accessible for general use. It has a wide range of clinical applications.

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Ian C. Han, MD, assistant professor in the Department of Ophthalmology and Visual Sciences, Institute for Vision Research, University of Iowa Hospital and Clinics, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.

With NASA’s sights set on Mars, continued research into further understanding and mitigating spaceflight-associated neuro-ocular syndrome is of the utmost importance for astronaut health and space exploration.

Rishi P. Singh, MD, highlights various treatment options available for the management of patients with age-related macular degeneration, as well as the status of potential therapies.

Results of a study analysing cytokine levels in the aqueous humour and serum of patients with nonproliferative diabetic retinopathy with and without diabetic macular oedema support further research investigating transforming growth factor-β-induced Gene Human Clone 30 (BIGH3) as a potential biomarker for DMO.

Study found that YAG laser vitreolysis was less invasive than pars plana vitrectomy for patients with vitreous opacities.

Community support is the most important factor in ascertaining effective treatments for paediatric eye diseases.

Diabetes mellitus, which is a common chronic disease in children, can lead to significant eye morbidities with long-lasting effects, including diabetic retinopathy. Treatment should be tailored to the individual patient.

Faricimab is the focus of the YOSEMITE and RHINE studies, which investigators say show that the investigational bispecific antibody has the potential to offer lasting vision improvements for patients with diabetic macular oedema.

Prospective randomised trial demonstrates clinical equivalence of biosimilar and reference ranibizumab

Good early adherence to label regimens can make a difference, yielding vision outcomes approaching those in clinical trials, emerging real-world studies of anti-VEGF for DMO suggest.

As OCT-A devices become faster, the algorithms advance and the instrument costs decrease, more widespread utilisation in retina practices is likely.

In this roundtable, members of the Ophthalmology Times Europe® Editorial Advisory Board consider the top challenges and opportunities that they anticipate will affect ophthalmology in Europe in 2021.

Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.

A case series of 13 young patients with Charles Bonnet syndrome, which is characterised by visual hallucinations in individuals who are experiencing sight loss, showed that the patients all had inherited retinal diseases or congenital eye disorders but there was no link with visual dysfunction.

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Tamer Mahmoud, MD, PhD, discusses autologous retinal transplant (ART) for macular holes, a procedure he developed, which is providing anatomic hole closure in the vast majority of cases as well as increases in visual acuity.